Is CNSP or PTPI more profitable?

Petros Pharmaceuticals' return on equity of -78.22% beat CNS Pharmaceuticals' return on equity. Company Net Margins Return on Equity Return on Assets CNS Pharmaceuticals N/A -204.25% -141.87% Petros Pharmaceuticals N/A -78.22% -23.50%

Which has better valuation & earnings, CNSP or NNVC?

NanoViricides is trading at a lower price-to-earnings ratio than CNS Pharmaceuticals, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio CNS Pharmaceuticals N/A N/A -$15.85M -$23.59 N/A NanoViricides N/A N/A -$8.29M -$0.43 N/A

Is CNSP or NNVC more profitable?

NanoViricides' return on equity of -87.90% beat CNS Pharmaceuticals' return on equity. Company Net Margins Return on Equity Return on Assets CNS Pharmaceuticals N/A -204.25% -141.87% NanoViricides N/A -87.90% -78.69%

Do analysts recommend CNSP or UPC?

CNS Pharmaceuticals currently has a consensus target price of $20.00, indicating a potential upside of 236.70%. Given CNS Pharmaceuticals' stronger consensus rating and higher possible upside, equities analysts clearly believe CNS Pharmaceuticals is more favorable than Universe Pharmaceuticals. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score CNS Pharmaceuticals 1 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00 Universe Pharmaceuticals 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has preferable earnings and valuation, CNSP or UPC?

Universe Pharmaceuticals has higher revenue and earnings than CNS Pharmaceuticals. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio CNS Pharmaceuticals N/A N/A -$15.85M -$23.59 N/A Universe Pharmaceuticals $17.86M 1.51 -$3.67M N/A N/A

Is CNSP or UPC more profitable?

Universe Pharmaceuticals' return on equity of 0.00% beat CNS Pharmaceuticals' return on equity. Company Net Margins Return on Equity Return on Assets CNS Pharmaceuticals N/A -204.25% -141.87% Universe Pharmaceuticals N/A N/A N/A

Do analysts prefer CNSP or BGM?

CNS Pharmaceuticals currently has a consensus target price of $20.00, indicating a potential upside of 236.70%. Given CNS Pharmaceuticals' stronger consensus rating and higher probable upside, analysts plainly believe CNS Pharmaceuticals is more favorable than BGM Group. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score CNS Pharmaceuticals 1 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00 BGM Group 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has stronger earnings & valuation, CNSP or BGM?

CNS Pharmaceuticals has higher earnings, but lower revenue than BGM Group. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio CNS Pharmaceuticals N/A N/A -$15.85M -$23.59 N/A BGM Group $37.92M 0.64 -$19.94M N/A N/A

Is CNSP or BGM more profitable?

BGM Group's return on equity of 0.00% beat CNS Pharmaceuticals' return on equity. Company Net Margins Return on Equity Return on Assets CNS Pharmaceuticals N/A -204.25% -141.87% BGM Group N/A N/A N/A

Do analysts prefer OPTH or CNSP?

CNS Pharmaceuticals has a consensus price target of $20.00, suggesting a potential upside of 236.70%. Given CNS Pharmaceuticals' stronger consensus rating and higher possible upside, analysts clearly believe CNS Pharmaceuticals is more favorable than Optimi Health. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Optimi Health 1 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.50 CNS Pharmaceuticals 1 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00

Is OPTH or CNSP more profitable?

Optimi Health's return on equity of 0.00% beat CNS Pharmaceuticals' return on equity. Company Net Margins Return on Equity Return on Assets Optimi Health N/A N/A N/A CNS Pharmaceuticals N/A -204.25% -141.87%

CNS Pharmaceuticals (CNSP) Competitors

$5.94 +0.11 (+1.89%)

Closing price 03:55 PM Eastern

Extended Trading

$5.51 -0.43 (-7.31%)

As of 06:03 PM Eastern

Compare

CNSP vs. PTPI, NNVC, UPC, BGM, and OPTH

Should you buy CNS Pharmaceuticals stock or one of its competitors? CNS Pharmaceuticals's main competitors and comparable companies include Petros Pharmaceuticals (PTPI), NanoViricides (NNVC), Universe Pharmaceuticals (UPC), BGM Group (BGM), and Optimi Health (OPTH). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "pharmaceuticals" industry.

How does CNS Pharmaceuticals compare to Petros Pharmaceuticals?

CNS Pharmaceuticals (NASDAQ:CNSP) and Petros Pharmaceuticals (NASDAQ:PTPI) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two companies based on the strength of their analyst recommendations, risk, valuation, earnings, profitability, media sentiment, institutional ownership and dividends.

CNS Pharmaceuticals has a beta of 3.05, suggesting that its share price is 205% more volatile than the broader market. Comparatively, Petros Pharmaceuticals has a beta of 1.88, suggesting that its share price is 88% more volatile than the broader market.

14.0% of CNS Pharmaceuticals shares are owned by institutional investors. Comparatively, 12.3% of Petros Pharmaceuticals shares are owned by institutional investors. 0.0% of CNS Pharmaceuticals shares are owned by insiders. Comparatively, 12.3% of Petros Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

In the previous week, CNS Pharmaceuticals had 1 more articles in the media than Petros Pharmaceuticals. MarketBeat recorded 1 mentions for CNS Pharmaceuticals and 0 mentions for Petros Pharmaceuticals. CNS Pharmaceuticals' average media sentiment score of 1.00 beat Petros Pharmaceuticals' score of 0.00 indicating that CNS Pharmaceuticals is being referred to more favorably in the media.

Company	Overall Sentiment
CNS Pharmaceuticals	Positive
Petros Pharmaceuticals	Neutral

CNS Pharmaceuticals presently has a consensus price target of $20.00, indicating a potential upside of 236.70%. Given CNS Pharmaceuticals' stronger consensus rating and higher probable upside, equities research analysts plainly believe CNS Pharmaceuticals is more favorable than Petros Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
CNS Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Petros Pharmaceuticals	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

Petros Pharmaceuticals' return on equity of -78.22% beat CNS Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
CNS Pharmaceuticals	N/A	-204.25%	-141.87%
Petros Pharmaceuticals	N/A	-78.22%	-23.50%

Petros Pharmaceuticals has higher revenue and earnings than CNS Pharmaceuticals. CNS Pharmaceuticals is trading at a lower price-to-earnings ratio than Petros Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
CNS Pharmaceuticals	N/A	N/A	-$15.85M	-$23.59	N/A
Petros Pharmaceuticals	$5.11M	0.03	-$8.16M	-$0.36	N/A

Summary

CNS Pharmaceuticals and Petros Pharmaceuticals tied by winning 7 of the 14 factors compared between the two stocks.

How does CNS Pharmaceuticals compare to NanoViricides?

CNS Pharmaceuticals (NASDAQ:CNSP) and NanoViricides (NYSE:NNVC) are both small-cap healthcare companies, but which is the better business? We will contrast the two companies based on the strength of their valuation, risk, dividends, analyst recommendations, profitability, institutional ownership, media sentiment and earnings.

CNS Pharmaceuticals currently has a consensus target price of $20.00, indicating a potential upside of 236.70%. NanoViricides has a consensus target price of $6.00, indicating a potential upside of 372.44%. Given NanoViricides' stronger consensus rating and higher possible upside, analysts clearly believe NanoViricides is more favorable than CNS Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
CNS Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
NanoViricides	0 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	3.00

CNS Pharmaceuticals has a beta of 3.05, suggesting that its stock price is 205% more volatile than the broader market. Comparatively, NanoViricides has a beta of 1.67, suggesting that its stock price is 67% more volatile than the broader market.

NanoViricides' return on equity of -87.90% beat CNS Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
CNS Pharmaceuticals	N/A	-204.25%	-141.87%
NanoViricides	N/A	-87.90%	-78.69%

NanoViricides is trading at a lower price-to-earnings ratio than CNS Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
CNS Pharmaceuticals	N/A	N/A	-$15.85M	-$23.59	N/A
NanoViricides	N/A	N/A	-$8.29M	-$0.43	N/A

14.0% of CNS Pharmaceuticals shares are held by institutional investors. Comparatively, 10.3% of NanoViricides shares are held by institutional investors. 0.0% of CNS Pharmaceuticals shares are held by insiders. Comparatively, 3.6% of NanoViricides shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

In the previous week, NanoViricides had 2 more articles in the media than CNS Pharmaceuticals. MarketBeat recorded 3 mentions for NanoViricides and 1 mentions for CNS Pharmaceuticals. CNS Pharmaceuticals' average media sentiment score of 1.00 beat NanoViricides' score of -0.19 indicating that CNS Pharmaceuticals is being referred to more favorably in the media.

Company	Overall Sentiment
CNS Pharmaceuticals	Positive
NanoViricides	Neutral

Summary

NanoViricides beats CNS Pharmaceuticals on 9 of the 13 factors compared between the two stocks.

How does CNS Pharmaceuticals compare to Universe Pharmaceuticals?

CNS Pharmaceuticals (NASDAQ:CNSP) and Universe Pharmaceuticals (NASDAQ:UPC) are both small-cap healthcare companies, but which is the better stock? We will compare the two businesses based on the strength of their profitability, media sentiment, earnings, analyst recommendations, valuation, risk, dividends and institutional ownership.

Universe Pharmaceuticals' return on equity of 0.00% beat CNS Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
CNS Pharmaceuticals	N/A	-204.25%	-141.87%
Universe Pharmaceuticals	N/A	N/A	N/A

CNS Pharmaceuticals has a beta of 3.05, meaning that its stock price is 205% more volatile than the broader market. Comparatively, Universe Pharmaceuticals has a beta of 1.52, meaning that its stock price is 52% more volatile than the broader market.

Universe Pharmaceuticals has higher revenue and earnings than CNS Pharmaceuticals.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
CNS Pharmaceuticals	N/A	N/A	-$15.85M	-$23.59	N/A
Universe Pharmaceuticals	$17.86M	1.51	-$3.67M	N/A	N/A

In the previous week, CNS Pharmaceuticals had 1 more articles in the media than Universe Pharmaceuticals. MarketBeat recorded 1 mentions for CNS Pharmaceuticals and 0 mentions for Universe Pharmaceuticals. CNS Pharmaceuticals' average media sentiment score of 1.00 beat Universe Pharmaceuticals' score of 0.00 indicating that CNS Pharmaceuticals is being referred to more favorably in the media.

Company	Overall Sentiment
CNS Pharmaceuticals	Positive
Universe Pharmaceuticals	Neutral

14.0% of CNS Pharmaceuticals shares are owned by institutional investors. Comparatively, 0.2% of Universe Pharmaceuticals shares are owned by institutional investors. 0.0% of CNS Pharmaceuticals shares are owned by company insiders. Comparatively, 57.4% of Universe Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

CNS Pharmaceuticals currently has a consensus target price of $20.00, indicating a potential upside of 236.70%. Given CNS Pharmaceuticals' stronger consensus rating and higher possible upside, equities analysts clearly believe CNS Pharmaceuticals is more favorable than Universe Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
CNS Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Universe Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Summary

CNS Pharmaceuticals beats Universe Pharmaceuticals on 7 of the 12 factors compared between the two stocks.

How does CNS Pharmaceuticals compare to BGM Group?

CNS Pharmaceuticals (NASDAQ:CNSP) and BGM Group (NASDAQ:BGM) are both small-cap healthcare companies, but which is the superior investment? We will compare the two businesses based on the strength of their institutional ownership, analyst recommendations, dividends, profitability, media sentiment, earnings, risk and valuation.

CNS Pharmaceuticals has a beta of 3.05, suggesting that its share price is 205% more volatile than the broader market. Comparatively, BGM Group has a beta of 1.8, suggesting that its share price is 80% more volatile than the broader market.

CNS Pharmaceuticals has higher earnings, but lower revenue than BGM Group.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
CNS Pharmaceuticals	N/A	N/A	-$15.85M	-$23.59	N/A
BGM Group	$37.92M	0.64	-$19.94M	N/A	N/A

BGM Group's return on equity of 0.00% beat CNS Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
CNS Pharmaceuticals	N/A	-204.25%	-141.87%
BGM Group	N/A	N/A	N/A

14.0% of CNS Pharmaceuticals shares are owned by institutional investors. 0.0% of CNS Pharmaceuticals shares are owned by company insiders. Comparatively, 58.7% of BGM Group shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

In the previous week, CNS Pharmaceuticals and CNS Pharmaceuticals both had 1 articles in the media. CNS Pharmaceuticals' average media sentiment score of 1.00 beat BGM Group's score of 0.67 indicating that CNS Pharmaceuticals is being referred to more favorably in the media.

Company	Overall Sentiment
CNS Pharmaceuticals	Positive
BGM Group	Positive

CNS Pharmaceuticals currently has a consensus target price of $20.00, indicating a potential upside of 236.70%. Given CNS Pharmaceuticals' stronger consensus rating and higher probable upside, analysts plainly believe CNS Pharmaceuticals is more favorable than BGM Group.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
CNS Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
BGM Group	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Summary

CNS Pharmaceuticals beats BGM Group on 7 of the 11 factors compared between the two stocks.

How does CNS Pharmaceuticals compare to Optimi Health?

Optimi Health (NASDAQ:OPTH) and CNS Pharmaceuticals (NASDAQ:CNSP) are both small-cap healthcare companies, but which is the superior business? We will contrast the two companies based on the strength of their dividends, media sentiment, risk, valuation, institutional ownership, earnings, analyst recommendations and profitability.

In the previous week, Optimi Health and Optimi Health both had 1 articles in the media. CNS Pharmaceuticals' average media sentiment score of 1.00 beat Optimi Health's score of 0.00 indicating that CNS Pharmaceuticals is being referred to more favorably in the news media.

Company	Overall Sentiment
Optimi Health	Neutral
CNS Pharmaceuticals	Positive

14.0% of CNS Pharmaceuticals shares are held by institutional investors. 0.0% of CNS Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Optimi Health's return on equity of 0.00% beat CNS Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Optimi Health	N/A	N/A	N/A
CNS Pharmaceuticals	N/A	-204.25%	-141.87%

Optimi Health has higher revenue and earnings than CNS Pharmaceuticals. Optimi Health is trading at a lower price-to-earnings ratio than CNS Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Optimi Health	$290K	98.40	-$1.12M	-$0.76	N/A
CNS Pharmaceuticals	N/A	N/A	-$15.85M	-$23.59	N/A

CNS Pharmaceuticals has a consensus price target of $20.00, suggesting a potential upside of 236.70%. Given CNS Pharmaceuticals' stronger consensus rating and higher possible upside, analysts clearly believe CNS Pharmaceuticals is more favorable than Optimi Health.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Optimi Health	1 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.50
CNS Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Summary

CNS Pharmaceuticals beats Optimi Health on 7 of the 12 factors compared between the two stocks.

Get CNS Pharmaceuticals News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding CNSP and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

CNSP vs. The Competition

Export

Metric	CNS Pharmaceuticals	Pharmaceuticals Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$8.52M	$12.53B	$7.36B	$12.81B
Dividend Yield	N/A	2.61%	2.53%	10.78%
P/E Ratio	-0.25	780.42	270.55	24.05
Price / Sales	N/A	758.40	636.07	105.35
Price / Cash	N/A	15.47	29.03	36.89
Price / Book	0.81	10.42	11.18	6.40
Net Income	-$15.85M	$2.79B	$3.46B	$347.95M
7 Day Performance	10.00%	2.25%	1.98%	0.91%
1 Month Performance	13.58%	4.72%	7.32%	5.10%
1 Year Performance	-8.33%	7.07%	24.76%	16.16%

CNS Pharmaceuticals Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
CNSP CNS Pharmaceuticals	3.0926 of 5 stars	$5.94 +1.9%	$20.00 +236.7%	-10.0%	$8.52M	N/A	N/A	5	Positive News Gap Down High Trading Volume
PTPI Petros Pharmaceuticals	N/A	$0.00 +3.7%	N/A	-84.4%	$87K	$5.11M	N/A	20	Gap Up
NNVC NanoViricides	1.5312 of 5 stars	$1.35 -0.7%	$6.00 +344.4%	-7.6%	$31.03M	N/A	N/A	20
UPC Universe Pharmaceuticals	0.6538 of 5 stars	$5.23 -9.5%	N/A	+52.3%	$28.39M	$17.86M	N/A	220	Positive News Gap Down
BGM BGM Group	0.8048 of 5 stars	$0.29 +6.1%	N/A	-96.6%	$28.31M	$37.92M	N/A	298	High Trading Volume

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:CNSP) was last updated on 8/24/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

CNS Pharmaceuticals (CNSP) Competitors

CNSP vs. PTPI, NNVC, UPC, BGM, and OPTH

How does CNS Pharmaceuticals compare to Petros Pharmaceuticals?

Summary

How does CNS Pharmaceuticals compare to NanoViricides?

Summary

How does CNS Pharmaceuticals compare to Universe Pharmaceuticals?

Summary

How does CNS Pharmaceuticals compare to BGM Group?

Summary

How does CNS Pharmaceuticals compare to Optimi Health?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

CNSP vs. The Competition

CNS Pharmaceuticals Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

CNS Pharmaceuticals (CNSP) Competitors

CNSP vs. PTPI, NNVC, UPC, BGM, and OPTH

How does CNS Pharmaceuticals compare to Petros Pharmaceuticals?

Which has more volatility and risk, CNSP or PTPI?

Do institutionals and insiders hold more shares of CNSP or PTPI?

Does the media favor CNSP or PTPI?

Do analysts rate CNSP or PTPI?

Is CNSP or PTPI more profitable?

Which has higher earnings and valuation, CNSP or PTPI?

Summary

How does CNS Pharmaceuticals compare to NanoViricides?

Do analysts prefer CNSP or NNVC?

Which has more risk and volatility, CNSP or NNVC?

Is CNSP or NNVC more profitable?

Which has better valuation & earnings, CNSP or NNVC?

Do insiders and institutionals have more ownership in CNSP or NNVC?

Does the media prefer CNSP or NNVC?

Summary

How does CNS Pharmaceuticals compare to Universe Pharmaceuticals?

Is CNSP or UPC more profitable?

Which has more volatility & risk, CNSP or UPC?

Which has preferable earnings and valuation, CNSP or UPC?

Does the media prefer CNSP or UPC?

Do institutionals & insiders have more ownership in CNSP or UPC?

Do analysts recommend CNSP or UPC?

Summary

How does CNS Pharmaceuticals compare to BGM Group?

Which has more volatility & risk, CNSP or BGM?

Which has stronger earnings & valuation, CNSP or BGM?

Is CNSP or BGM more profitable?

Do institutionals and insiders believe in CNSP or BGM?

Does the media prefer CNSP or BGM?

Do analysts prefer CNSP or BGM?

Summary

How does CNS Pharmaceuticals compare to Optimi Health?

Does the media refer more to OPTH or CNSP?

Do institutionals and insiders hold more shares of OPTH or CNSP?

Is OPTH or CNSP more profitable?

Which has preferable valuation & earnings, OPTH or CNSP?

Do analysts prefer OPTH or CNSP?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

CNSP vs. The Competition

CNS Pharmaceuticals Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools